In a neuroblastoma study in immunodeficient NSG mice, it was shown that immunotherapy with the anti-GD2 antibody dinutuximab combined with activated NK cells is suppressed by endoglin-positive cells in the tumor microenvironment. The gene discussed is ENG; the disease is neoplasm.